Overview

A Study of Oraxol® in Gastric Cancer Patients

Status:
Unknown status

Trial end date:
2012-12-01

Target enrollment:

Participant gender:

Summary

The main objectives of this study are to determine the maximum tolerated dose (MTD) and recommend dose (RD) of Oraxol® in Phase I and to determine the objective response rate of Oraxol® in Phase II.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Hanmi Pharmaceutical Company Limited

Treatments:

Albumin-Bound Paclitaxel
Paclitaxel